CliffBio
small molecule

ENBUMYST

BUMETANIDE

Loss of exclusivityMay 2045latest FDA-listed patent expiry
CompanyCorstasis Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameENBUMYST
Active ingredientBUMETANIDE
Strength0.5MG/SPRAY
Dosage formSPRAY
RouteNASAL
ModalitySmall molecule
FDA approvalSeptember 2025
Marketing statusRX

Listed patents

PatentExpiresType
12558330May 2045product
12329731December 2040product
11260038December 2040use U-4279
11123319December 2040product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.